Anti-PLOD2 antibody produced in mouse | MilliporeSigma SAB1400213 product information

This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.

product summary

company name :

MilliporeSigma

other brands :

FLUKA, Sigma-Aldrich, Roche Applied Science

product type :

antibody

product name :

Anti-PLOD2 antibody produced in mouse

catalog :

SAB1400213

clonality :

polyclonal

host :

mouse

conjugate :

nonconjugated

reactivity :

human

application :

western blot, immunocytochemistry

citations: 1

Published Application/Species/Sample/Dilution	Reference
immunocytochemistry; human; 1:100; fig 1	Mia M, Bank R. The pro-fibrotic properties of transforming growth factor on human fibroblasts are counteracted by caffeic acid by inhibiting myofibroblast formation and collagen synthesis. Cell Tissue Res. 2016;363:775-89 pubmed publisher

product information

cat no :

SAB1400213

brand :

SIGMA

name :

Anti-PLOD2 antibody produced in mouse

prod type :

Chemical

name suffix :

IgG fraction of antiserum, buffered aqueous solution

storage :

-20C

storage temp :

-20C

physical form :

Solution in phosphate buffered saline, pH 7.2

shipped in :

dry ice

syns :

Anti-LH2; Anti-TLH

form :

buffered aqueous solution

antibody form :

IgG fraction of antiserum

application(s) :

capture ELISA: suitable; western blot: suitable; indirect immunofluorescence: suitable

species reactivity :

human

immunogen :

PLOD2 (NP_891988.1, a.a. 1-758) full-length human protein.

immunogen sequence :

(without GST)
MGGCTVKPQLLLLALVLHPWNPCLGADSEKPSSIPTDKL
LVITVATKESDGFHRFMQSAKYFNYTVKVLGQGEEWRGG
DGINSIGGGQKVRLMKEVMEHYADQDDLVVMFTECFDVI
FAGGPEEVLKKFQKANHKVVFAADGILWPDKRLADKYPV
VHIGKRYLNSGGFIGYAPYVNRIVQQWNLQDNDDDQLFY
TKVYIDPLKREAINITLDHKCKIFQTLNGAVDEVVLKFE
NGKARAKNTFYETLPVAINGNGPTKILLNYFGNYVPNSW
TQDNGCTLCEFDTVDLSAVDVHPNVSIGVFIEQPTPFLP
RFLDILLTLDYPKEALKLFIHNKEVYHEKDIKVFFDKAK
HEIKTIKIVGPEENLSQAEARNMGMDFCRQDEKCDYYFS
VDADVVLTNPRTLKILIEQNRKIIAPLVTRHGKLWSNFW
GALSPDGYYARSEDYVDIVQGNRVGVWNVPYMANVYLIK
GKTLRSEMNERNYFVRDKLDPDMALCRNAREMTLQREKD
SPTPETFQMLSPPKGVFMYISNRHEFGRLLSTANYNTSH
YNNDLWQIFENPVDWKEKYINRDYSKIFTENIVEQPCPD
VFWFPIFSEKACDELVEEMEHYGKWSGGKHHDSRISGGY
ENVPTDDIHMKQVDLENVWLHFIREFIAPVTLKVFAGYY
TKGFALLNFVVKYSPERQRSLRPHHDASTFTINIALNNV
GEDFQGGGCKFLRYNCSIESPRKGWSFMHPGRLTHLHEG
LPVKNGTRYIAVSFIDP